

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

<https://marketpublishers.com/r/GD274EBBE68FEN.html>

Date: October 2025

Pages: 456

Price: US\$ 4,950.00 (Single User License)

ID: GD274EBBE68FEN

Abstracts

The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer's disease, obstructive sleep apnea, and obesity. The rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers.

The patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024.

Based on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter. Patented GLP-1 agonists dominate prescribing patterns due to their robust

clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth.

By end user, the home-care settings and fitness/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024.

Based on end user, the GLP-1 agonists market is segmented into home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management. Home care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment.

The US dominated the GLP-1 agonists market in 2024.

In 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply-side- 70% and Demand-side 30%

By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25%

By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

Novo Nordisk A/S (Denmark)

Eli Lilly and Company (US)

Sanofi (France)

Hansoh Pharmaceutical Group Co., Ltd. (China)

Boehringer Ingelheim International GmbH (Germany)

Innovent (China)

Sun Pharmaceutical Industries Ltd. (India)

Pegbio Co. Ltd (China)

Structure Therapeutics (US)

Viking Therapeutics (US)

Amgen Inc. (Switzerland)

Altimune (US)

Glenmark (India)

Biocon (India)

Teva Pharmaceuticals (Israel)

Terns Pharmaceuticals, Inc. (US)

VTV Therapeutics (US)

F. Hoffmann-La Roche Ltd (Switzerland)

Hanmi Pharm Co., Ltd. (South Korea)

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)

Pfizer Inc. (US)

MetaVia Inc (US)

SCOHIA PHARMA, Inc. (Japan)

Sciwind Biosciences Co., Ltd. (China)

i2o Therapeutics, Inc. (US)

Biomed Industries, Inc. (US)

Neuraly Inc. (US)

Research Coverage

This research report categorizes the GLP-1 agonists market by product (ozempic, wegovy, mounjaro, zepbound, rybelsus, trulicity, orforglipron, cagrisema, survodutide, retatrutide, semaglutide biosimilars, other GLP-1 biosimilars, other products), molecule (Semaglutide, Tirzepatide, Dulaglutide, Cagrilintide semaglutide combination, Orforglipron, Survodutide, Retatrutide, Other molecules), type (patented, biosimilars), format (single-dose, multi-dose, tablets), indication (diabetes, obesity, other indications), route of administration (subcutaneous, oral), end user (home-care settings and fitness/weight management facilities, long-term care facilities, and hospitals and specialty clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the GLP-1 agonists market. A thorough analysis of the key industry players has provided insights into their business overview, products offered, key strategies, collaborations, partnerships, and agreements. Product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements are the recent

developments associated with the GLP-1 agonists market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

Analysis of key drivers (expanding manufacturing capacity, shift of GLP-1 drugs from diabetes specialty to broader treatment option, growing prevalence of obesity and type 2 diabetes), restraints (stringent cost and payer controls), opportunities (increasing studies on oral GLP-1), and challenges (counterfeits and compounded GLP-1 gray market, safety, tolerability, persistence issues) influencing the growth of the market.

Product Development/Innovation: Detailed insights on newly approved and launched products of the GLP-1 agonists market

Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.

Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the GLP-1 agonists market

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of key players, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product approvals and launches, acquisitions, partnerships, agreements, collaborations, expansions, recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 agonists market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Key objectives of secondary research
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries
 - 2.1.2.2 Key objectives of primary research
- 2.2 MARKET SIZE ESTIMATION
 - 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
 - 2.2.2 SECONDARY DATA & PRIMARY INTERVIEWS
 - 2.2.3 SEGMENTAL MARKET SIZE ASSESSMENT
- 2.3 MARKET GROWTH FORECAST
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

- 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
- 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
- 3.3 DISRUPTIVE TRENDS SHAPING GLP-1 AGONISTS MARKET
- 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patent...)

- 4.1 GLOBAL GLP-1 AGONISTS MARKET SNAPSHOT
- 4.2 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION AND COUNTRY, 2024
- 4.3 GLP-1 AGONISTS MARKET, BY FORMAT, 2024
- 4.4 GLP-1 AGONISTS MARKET, BY END USER, 2024
- 4.5 GLP-1 AGONISTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 4.6 UNMET NEEDS & WHITE SPACES
- 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
 - 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
- 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
- 4.9 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.10 GLP-1 AGONISTS PRODUCTION CAPACITY HIGHLIGHTS
- 4.11 KEY DRUG LAUNCHES EXPECTED, 2025–2033
- 4.12 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
 - 5.2.1 DRIVERS
 - 5.2.1.1 Expanding manufacturing capacities of large pharmaceutical companies
 - 5.2.1.2 Shift of GLP-1 drugs from diabetes specialty to broader treatment options
 - 5.2.1.3 Rising prevalence of obesity and type-2 diabetes
 - 5.2.2 RESTRAINTS
 - 5.2.2.1 Stringent cost and payer controls
 - 5.2.3 OPPORTUNITIES
 - 5.2.3.1 Increasing studies on oral GLP-1
 - 5.2.4 CHALLENGES
 - 5.2.4.1 Counterfeits and compounded GLP-1 gray market
 - 5.2.4.2 Safety, tolerability, and persistence issues
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
 - 5.3.1 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES
- 5.4 PRICING ANALYSIS
 - 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024
 - 5.4.2 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024
 - 5.4.3 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY

REGION, 2022–2024

5.4.4 FACTORS IMPACTING GLP-1 AGONISTS PRICING

5.5 INDUSTRY TRENDS

5.5.1 SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS

5.5.2 VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND

5.6 TECHNOLOGY ANALYSIS

5.6.1 KEY TECHNOLOGIES

5.6.1.1 Chemical synthesis

5.6.1.2 Recombinant DNA technology

5.6.2 COMPLEMENTARY TECHNOLOGIES

5.6.2.1 Peptelligence

5.6.2.2 PEGylation and polymer encapsulation

5.6.3 ADJACENT TECHNOLOGIES

5.6.3.1 Hydrogel depot technologies

5.6.3.2 Technologies for oral delivery of GLP-1 analogues

5.7 PIPELINE ANALYSIS

5.8 TECHNOLOGY/PRODUCT ROADMAP

5.9 VALUE CHAIN ANALYSIS

5.10 ECOSYSTEM ANALYSIS

5.10.1 ROLE IN ECOSYSTEM

5.11 PORTER'S FIVE FORCES ANALYSIS

5.11.1 THREAT OF NEW ENTRANTS

5.11.2 THREAT OF SUBSTITUTES

5.11.3 BARGAINING POWER OF SUPPLIERS

5.11.4 BARGAINING POWER OF BUYERS

5.11.5 INTENSITY OF COMPETITIVE RIVALRY

5.12 REGULATORY ANALYSIS

5.12.1 REGULATORY LANDSCAPE

5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER

ORGANIZATIONS

5.13 KEY CONFERENCES & EVENTS, 2025–2026

5.14 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.14.2 KEY BUYING CRITERIA

5.14.3 ADOPTION BARRIER & INTERNAL FRICTION

5.15 INVESTMENT/FUNDING SCENARIO

5.16 REIMBURSEMENT SCENARIO

5.17 IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET

5.17.1 IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES

- 5.17.2 AI USE CASES
- 5.17.3 KEY COMPANIES IMPLEMENTING AI
- 5.17.4 FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM
- 5.18 IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET
 - 5.18.1 INTRODUCTION
 - 5.18.2 KEY TARIFF RATES
 - 5.18.3 PRICE IMPACT ANALYSIS
 - 5.18.4 IMPACT ON REGION
 - 5.18.4.1 North America
 - 5.18.4.2 Europe
 - 5.18.4.3 Asia Pacific
 - 5.18.5 IMPACT ON END-USE INDUSTRIES
 - 5.18.5.1 Hospitals & specialty centers
 - 5.18.5.2 Long-term care facilities

6 GLP-1 AGONISTS MARKET, BY PRODUCT

- 6.1 INTRODUCTION
- 6.2 GLP-1 AGONISTS VOLUME MARKET ESTIMATION
- 6.3 OZEMPIC
 - 6.3.1 ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET
- 6.4 TRULICITY
 - 6.4.1 LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH
- 6.5 MOUNJARO
 - 6.5.1 DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION
- 6.6 WEGOVY
 - 6.6.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH
- 6.7 RYBELSUS
 - 6.7.1 EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS
- 6.8 ZEPBOUND
 - 6.8.1 INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL
- 6.9 ORFORGLIPRON
 - 6.9.1 ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE

LOGISTICS AND NO FASTING WINDOW

6.10 CAGRISEMA

6.10.1 FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH

6.11 SURVODUTIDE

6.11.1 STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH

6.12 RETATRUTIDE

6.12.1 STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET

6.13 SEMAGLUTIDE BIOSIMILARS

6.13.1 HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH

6.14 OTHER GLP-1 BIOSIMILARS

6.15 OTHER PRODUCTS

7 GLP-1 AGONISTS MARKET, BY MOLECULE

7.1 INTRODUCTION

7.2 SEMAGLUTIDE

7.2.1 PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH

7.3 TIRZEPATIDE

7.3.1 STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST

7.4 DULAGLUTIDE

7.4.1 USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS

7.5 CAGRILINTIDE SEMAGLUTIDE COMBINATION

7.5.1 SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH

7.6 ORFORGLIPRON

7.6.1 NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS

7.7 SURVODUTIDE

7.7.1 DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH

7.8 RETATRUTIDE

7.8.1 TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT

MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL

7.9 OTHER MOLECULES

8 GLP-1 AGONISTS MARKET, BY TYPE

8.1 INTRODUCTION

8.2 PATENTED PRODUCTS

8.2.1 PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY

8.3 BIOSIMILARS

8.3.1 SEMAGLUTIDE BIOSIMILARS

8.3.1.1 Upcoming patent expiry for major drugs in key markets to increase biosimilar adoption

8.3.2 OTHER BIOSIMILARS

9 GLP-1 AGONISTS MARKET, BY INDICATION

9.1 INTRODUCTIONS

9.2 DIABETES

9.2.1 HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION

9.3 OBESITY

9.3.1 STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET

9.4 OTHER INDICATIONS

10 GLP-1 AGONISTS MARKET, BY FORMAT

10.1 INTRODUCTION

10.2 SINGLE-DOSE FORMATS

10.2.1 EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH

10.3 MULTI-DOSE FORMATS

10.3.1 COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS

10.4 AUTOINJECTORS

10.4.1 SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION

11 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION

11.1 INTRODUCTION

11.2 SUBCUTANEOUS ADMINISTRATION

11.2.1 PEN INJECTORS

11.2.1.1 Easy monitoring of volume and dosage strength to support adoption

11.2.2 AUTOINJECTORS

11.2.2.1 Simplified injection process with lower human errors to support adoption

11.3 ORAL ADMINISTRATION

11.3.1 ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

12 GLP-1 AGONISTS MARKET, BY END USER

12.1 INTRODUCTION

12.2 HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES

12.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH

12.3 LONG-TERM CARE FACILITIES

12.3.1 GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH

12.4 HOSPITALS & SPECIALTY CLINICS

12.4.1 ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET

13 GLP-1 AGONISTS MARKET, BY REGION

13.1 INTRODUCTION

13.2 NORTH AMERICA

13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

13.2.2 US

13.2.2.1 US to dominate North American GLP-1 agonists market during forecast period

13.2.3 CANADA

13.2.3.1 Favorable funding scenario and presence of strong research infrastructure to support market growth

13.3 EUROPE

13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

13.3.2 GERMANY

13.3.2.1 Expertise in biotechnology and reputation as leading pharmaceutical manufacturing hub to expedite market growth

13.3.3 UK

13.3.3.1 Growing R&D initiatives for development of GLP-1 agonists drugs to support market growth

13.3.4 FRANCE

13.3.4.1 Favorable regulatory scenario and strong research infrastructure to propel market growth

13.3.5 ITALY

13.3.5.1 Presence of key pharmaceutical & biotechnology companies to boost market growth

13.3.6 SPAIN

13.3.6.1 High incidence of diabetes and obesity to augment market adoption of GLP-1 therapeutic drugs

13.3.7 NETHERLANDS

13.3.7.1 Strong focus on pharmaceutical R&D to support market growth

13.3.8 REST OF EUROPE

13.4 ASIA PACIFIC

13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

13.4.2 CHINA

13.4.2.1 Increasing endorsements of anti-obesity drugs by celebrities to drive market adoption

13.4.3 JAPAN

13.4.3.1 High diabetic population and favorable regulatory scenario to aid market growth

13.4.4 INDIA

13.4.4.1 Growing demand for cost-effective and accessible anti-obesity medications to aid market growth

13.4.5 AUSTRALIA

13.4.5.1 Significant government investment in obesity prevention to fuel market growth

13.4.6 SOUTH KOREA

13.4.6.1 Increasing strategic collaborations in obesity drugs to propel market growth

13.4.7 REST OF ASIA PACIFIC

13.5 LATIN AMERICA

13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

13.5.2 BRAZIL

13.5.2.1 Increasing partnerships with global pharmaceutical companies and rising diabetes cases to drive Brazilian market

13.5.3 MEXICO

13.5.3.1 Growing diabetes and obesity prevalence to support market growth

13.5.4 REST OF LATIN AMERICA

13.6 MIDDLE EAST

13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

13.6.2 GCC COUNTRIES

13.6.2.1 Kingdom of Saudi Arabia

13.6.2.1.1 Pricing oversight of Saudi Food and Drug Authority and strong sales from leading industry players to drive market

13.6.2.2 UAE

13.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to spur market growth

13.6.2.3 Rest of GCC Countries

13.6.3 REST OF MIDDLE EAST

13.7 AFRICA

13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH

13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

14.1 INTRODUCTION

14.2 KEY STRATEGIES/RIGHT TO WIN

14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET

14.3 REVENUE ANALYSIS, 2020–2024

14.4 MARKET SHARE ANALYSIS, 2024

14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

14.5.1 STARS

14.5.2 EMERGING LEADERS

14.5.3 PERVASIVE PLAYERS

14.5.4 PARTICIPANTS

14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024

14.6.1 STARS

14.6.2 EMERGING LEADERS

14.6.3 PERVASIVE PLAYERS

14.6.4 PARTICIPANTS

14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

14.6.5.1 Company footprint

14.6.5.2 Region footprint

14.6.5.3 Format footprint

14.6.5.4 Route of administration footprint

14.6.5.5 Indication footprint

14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024

14.7.1 PROGRESSIVE COMPANIES

14.7.2 RESPONSIVE COMPANIES

14.7.3 DYNAMIC COMPANIES

14.7.4 STARTING BLOCKS

14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

14.7.5.1 Competitive benchmarking of key startups/SMEs

14.8 COMPANY VALUATION & FINANCIAL METRICS

14.8.1 FINANCIAL METRICS

14.8.2 COMPANY VALUATION

14.9 BRAND/PRODUCT COMPARISON

14.10 COMPETITIVE SCENARIO

14.10.1 PRODUCT APPROVALS

14.10.2 DEALS

14.10.3 EXPANSIONS

14.10.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

15.1 INTRODUCTION

15.2 KEY PLAYERS

15.2.1 NOVO NORDISK A/S

15.2.1.1 Business overview

15.2.1.2 Products offered

15.2.1.3 Recent developments

15.2.1.3.1 Product approvals

15.2.1.3.2 Deals

15.2.1.3.3 Expansions

15.2.1.3.4 Other developments

15.2.1.4 MnM view

15.2.1.4.1 Right to win

15.2.1.4.2 Strategic choices

15.2.1.4.3 Weaknesses & competitive threats

15.2.2 ELI LILLY AND COMPANY

15.2.2.1 Business overview

15.2.2.2 Products offered

15.2.2.3 Recent developments

- 15.2.2.3.1 Product approvals
- 15.2.2.3.2 Deals
- 15.2.2.3.3 Expansions
- 15.2.2.4 MnM view
 - 15.2.2.4.1 Right to win
 - 15.2.2.4.2 Strategic choices
 - 15.2.2.4.3 Weaknesses & competitive threats
- 15.2.3 SANOFI
 - 15.2.3.1 Business overview
 - 15.2.3.2 Products offered
 - 15.2.3.3 MnM view
 - 15.2.3.3.1 Key strengths
 - 15.2.3.3.2 Strategic choices
 - 15.2.3.3.3 Weaknesses & competitive threats
- 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
 - 15.2.4.1 Business overview
 - 15.2.4.2 Products offered
- 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
 - 15.2.5.1 Business overview
 - 15.2.5.2 Products offered (in pipeline)
 - 15.2.5.3 Recent developments
 - 15.2.5.3.1 Other developments
- 15.2.6 INNOVENT
 - 15.2.6.1 Business overview
 - 15.2.6.2 Products offered (in pipeline)
 - 15.2.6.3 Recent developments
 - 15.2.6.3.1 Product approvals
 - 15.2.6.3.2 Other developments
- 15.2.7 PEGBIO CO., LTD.
 - 15.2.7.1 Business overview
 - 15.2.7.2 Products offered (in pipeline)
- 15.2.8 SCIWIND BIOSCIENCES CO., LTD.
 - 15.2.8.1 Business overview
 - 15.2.8.2 Products offered (in pipeline)
 - 15.2.8.3 Recent developments
 - 15.2.8.3.1 Deals
 - 15.2.8.3.2 Other developments
- 15.2.9 ZEALAND PHARMA
 - 15.2.9.1 Business overview

- 15.2.9.2 Products offered (in pipeline)
- 15.2.9.3 Recent developments
 - 15.2.9.3.1 Deals
 - 15.2.9.3.2 Other developments
- 15.2.10 STRUCTURE THERAPEUTICS, INC.
 - 15.2.10.1 Business overview
 - 15.2.10.2 Products offered (in pipeline)
 - 15.2.10.3 Recent developments
 - 15.2.10.3.1 Other developments
- 15.2.11 VIKING THERAPEUTICS
 - 15.2.11.1 Business overview
 - 15.2.11.2 Products offered (in pipeline)
 - 15.2.11.3 Recent developments
 - 15.2.11.3.1 Deals
- 15.2.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
 - 15.2.12.1 Business overview
 - 15.2.12.2 Products offered (in pipeline)
- 15.2.13 VTV THERAPEUTICS
 - 15.2.13.1 Business overview
 - 15.2.13.2 Products offered (in pipeline)
- 15.2.14 ALTIMMUNE
 - 15.2.14.1 Business overview
 - 15.2.14.2 Products offered (in pipeline)
 - 15.2.14.3 Recent developments
 - 15.2.14.3.1 Other developments
- 15.2.15 AMGEN INC.
 - 15.2.15.1 Business overview
 - 15.2.15.2 Products offered (in pipeline)
- 15.2.16 GLENMARK PHARMACEUTICALS LTD.
 - 15.2.16.1 Business overview
 - 15.2.16.2 Products offered (in pipeline)
 - 15.2.16.3 Recent developments
 - 15.2.16.3.1 Product launches
- 15.2.17 BIOCON
 - 15.2.17.1 Business overview
 - 15.2.17.2 Products offered (in pipeline)
 - 15.2.17.3 Recent developments
 - 15.2.17.3.1 Product launches and approvals
 - 15.2.17.3.2 Deals

15.2.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.

15.2.18.1 Business overview

15.2.18.2 Products offered (in pipeline)

15.2.18.3 Recent developments

15.2.18.3.1 Product launches

15.2.19 F. HOFFMANN-LA ROCHE LTD.

15.2.19.1 Business overview

15.2.19.2 Products offered (in pipeline)

15.2.19.3 Recent developments

15.2.19.3.1 Deals

15.3 OTHER PLAYERS

15.3.1 TERNS PHARMACEUTICALS, INC.

15.3.2 METAVIA

15.3.3 SCOHIA PHARMA, INC.

15.3.4 REGOR THERAPEUTICS GROUP

15.3.5 NEURALY INC.

15.3.6 I2O THERAPEUTICS, INC.

15.3.7 PFIZER INC.

15.3.8 HANMI PHARM CO.,LTD.

15.3.9 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.

15.3.10 BIOMED INDUSTRIES, INC.

16 APPENDIX

16.1 DISCUSSION GUIDE

16.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL

16.3 CUSTOMIZATION OPTIONS

16.4 RELATED REPORTS

16.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 GLP-1 AGONISTS MARKET: INCLUSIONS & EXCLUSIONS

TABLE 2 GLP-1 AGONISTS MARKET: RISK ANALYSIS

TABLE 3 GLP-1 AGONISTS MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES

TABLE 4 GLP-1 AGONISTS MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS

TABLE 5 EXPECTED KEY LAUNCHES IN GLP-1 AGONISTS MARKET, 2025–2033

TABLE 6 GLP-1 AGONISTS MARKET: IMPACT ANALYSIS

TABLE 7 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES

TABLE 8 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)

TABLE 9 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022–2024 (USD)

TABLE 10 GLP-1 AGONISTS IN CLINICAL PIPELINE (AS OF SEPTEMBER 2025)

TABLE 11 GLP-1 AGONISTS MARKET: ROLE IN ECOSYSTEM

TABLE 12 GLP-1 AGONISTS MARKET: PORTER'S FIVE FORCES

TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 17 LIST OF KEY CONFERENCES & EVENTS IN GLP-1 AGONISTS MARKET, JANUARY 2025–DECEMBER 2026

TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE

TABLE 19 BUYING CRITERIA FOR GLP-1 AGONIST PRODUCTS, BY END USER

TABLE 20 GLP-1 AGONISTS: ADOPTION BARRIER & INTERNAL FRICTION

TABLE 21 KEY COMPANIES IMPLEMENTING AI IN GLP-1 AGONISTS MARKET

TABLE 22 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 23 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (MILLION UNITS)

TABLE 24 GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION)

TABLE 25 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 26 EUROPE: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 27 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 28 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 29 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024–2033 (USD BILLION)

TABLE 30 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 31 GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 33 EUROPE: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 34 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 35 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 36 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 37 GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION)

TABLE 38 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 39 EUROPE: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 40 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 41 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 42 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024–2033 (USD BILLION)

TABLE 43 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 44 GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION)

TABLE 45 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY

COUNTRY, 2024–2033 (USD BILLION)

TABLE 46 EUROPE: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 47 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 48 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 49 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024–2033 (USD BILLION)

TABLE 50 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 51 GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION)

TABLE 52 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 53 EUROPE: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 54 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 55 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 56 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024–2033 (USD BILLION)

TABLE 57 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 58 GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION)

TABLE 59 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 60 EUROPE: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 61 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 62 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 63 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024–2033 (USD BILLION)

TABLE 64 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 65 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 66 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 67 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 68 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 69 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 70 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 71 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 72 GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION)

TABLE 73 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 74 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 75 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 76 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 77 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024–2033 (USD BILLION)

TABLE 78 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 79 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 80 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 81 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 82 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 83 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 84 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY

REGION, 2024–2033 (USD BILLION)

TABLE 85 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 86 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 87 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 88 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 89 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 90 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 91 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 92 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 93 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 94 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 95 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 96 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 97 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 98 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 99 GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 100 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 101 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 102 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 103 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

- TABLE 104 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)
- TABLE 105 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 106 GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION)
- TABLE 107 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 108 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 109 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 110 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 111 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024–2033 (USD BILLION)
- TABLE 112 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 113 GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)
- TABLE 114 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)
- TABLE 115 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 116 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 117 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 118 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 119 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)
- TABLE 120 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 121 GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION)
- TABLE 122 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)
- TABLE 123 EUROPE: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 124 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 125 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 126 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 127 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 128 GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 129 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 130 EUROPE: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 131 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 132 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 133 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 134 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 135 GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 136 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 137 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 138 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 139 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 140 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 141 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 142 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 143 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON,

BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 144 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 145 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 146 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 147 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024–2033 (USD BILLION)

TABLE 148 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 149 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 150 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 151 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 152 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 153 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 154 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 155 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 156 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 157 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 158 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 159 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 160 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 161 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024–2033 (USD BILLION)

TABLE 162 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 163 GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION)

TABLE 164 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 165 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 166 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 167 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 168 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024–2033 (USD BILLION)

TABLE 169 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 170 GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 171 GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 172 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 173 EUROPE: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 174 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 175 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 176 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024–2033 (USD BILLION)

TABLE 177 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 178 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 179 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 180 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 181 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 182 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 183 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024–2033 (USD BILLION)

TABLE 184 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 185 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 186 SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 187 NORTH AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 188 EUROPE: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 189 ASIA PACIFIC: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 190 LATIN AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 191 MIDDLE EAST: SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 192 GCC COUNTRIES: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 193 OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 194 NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 195 EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 196 ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 197 LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 198 MIDDLE EAST: OTHER BIOSIMILARS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 199 GCC COUNTRIES: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 200 GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 201 GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION)

TABLE 202 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 203 EUROPE: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY,

2024–2033 (USD BILLION)

TABLE 204 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 205 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 206 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024–2033 (USD BILLION)

TABLE 207 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 208 GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 209 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 210 EUROPE: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 211 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 212 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 213 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024–2033 (USD BILLION)

TABLE 214 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 215 GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION)

TABLE 216 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 217 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 218 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 219 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 220 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2033 (USD BILLION)

TABLE 221 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 222 GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 223 GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY

REGION, 2024–2033 (USD BILLION)

TABLE 224 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 225 EUROPE: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 226 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 227 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 228 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 229 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 230 GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 231 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 232 EUROPE: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 233 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 234 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 235 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024–2033 (USD BILLION)

TABLE 236 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 237 GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION)

TABLE 238 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 239 EUROPE: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 240 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 241 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 242 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024–2033 (USD BILLION)

TABLE 243 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 244 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 245 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 246 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 247 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 248 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 249 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 250 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 251 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 252 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 253 PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 254 NORTH AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 255 EUROPE: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 256 ASIA PACIFIC: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 257 LATIN AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 258 MIDDLE EAST: PEN INJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 259 GCC COUNTRIES: PEN INJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 260 AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 262 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 263 ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033

(USD BILLION)

TABLE 264 LATIN AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 265 MIDDLE EAST: AUTOINJECTORS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 266 GCC COUNTRIES: AUTOINJECTORS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 267 GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 268 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 269 EUROPE: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 270 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 271 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 272 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024–2033 (USD BILLION)

TABLE 273 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 274 GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 275 GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 276 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 277 EUROPE: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 278 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 279 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 280 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION,

2024–2033 (USD BILLION)

TABLE 281 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 282 GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 283 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 284 EUROPE: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 285 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 286 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 287 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024–2033 (USD BILLION)

TABLE 288 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 289 GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)

TABLE 290 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 291 EUROPE: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 292 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 293 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 294 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024–2033 (USD BILLION)

TABLE 295 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 296 GLP-1 AGONISTS MARKET, BY REGION, 2024–2033 (USD BILLION)

TABLE 297 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 298 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 299 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 300 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 301 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 302 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 303 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 304 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 305 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 306 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 307 NORTH AMERICA: KEY MACROINDICATORS

TABLE 308 US: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 309 US: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 310 US: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 311 US: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 312 US: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 313 US: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 314 US: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 315 US: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 316 US: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 317 CANADA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 318 CANADA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 319 CANADA: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 320 CANADA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)

TABLE 321 CANADA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 322 CANADA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 323 CANADA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 324 CANADA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 325 CANADA: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 326 EUROPE: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024–2033 (USD BILLION)

TABLE 327 EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 328 EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 329 EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 330 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 331 EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 332 EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 333 EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 334 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 335 EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 336 EUROPE: KEY MACROINDICATORS

TABLE 337 GERMANY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 338 GERMANY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 339 GERMANY: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 340 GERMANY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE,

2024–2033 (USD BILLION)

TABLE 341 GERMANY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

TABLE 342 GERMANY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024–2033 (USD BILLION)

TABLE 343 GERMANY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2033 (USD BILLION)

TABLE 344 GERMANY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024–2033 (USD BILLION)

TABLE 345 GERMANY: GLP-1 AGONISTS MARKET, BY END USER, 2024–2033 (USD BILLION)

TABLE 346 UK: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024–2033 (USD BILLION)

TABLE 347 UK: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024–2033 (USD BILLION)

TABLE 348 UK: GLP-1 AGONISTS MARKET, BY TYPE, 2024–2033 (USD BILLION)

TABLE 349 UK: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024–2033 (USD BILLION)

TABLE 350 UK: GLP-1 AGONISTS MARKET, BY INDICATION, 2024–2033 (USD BILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 GLP-1 AGONISTS MARKET: YEARS CONSIDERED

FIGURE 3 GLP-1 AGONISTS MARKET: RESEARCH DESIGN

FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS

FIGURE 5 GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 6 GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024

FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS

FIGURE 8 GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH

FIGURE 9 CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 2025–2033

FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET

FIGURE 11 GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY

FIGURE 12 GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS. 2033 (USD BILLION)

FIGURE 13 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2033 (USD BILLION)

FIGURE 14 GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS. 2030 (USD BILLION)

FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)

FIGURE 16 REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET

FIGURE 17 INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH

FIGURE 18 US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024

FIGURE 19 SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024

FIGURE 20 HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024

FIGURE 21 KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 22 GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

FIGURE 23 US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)

FIGURE 24 GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 25 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022–2024 (USD)

FIGURE 26 GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS

FIGURE 27 GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS

FIGURE 28 GLP-1 AGONISTS MARKET: PORTER'S FIVE FORCES ANALYSIS

FIGURE 29 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE

FIGURE 30 KEY BUYING CRITERIA FOR END USERS

FIGURE 31 AI USE CASES IN GLP-1 AGONISTS MARKET

FIGURE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT

FIGURE 33 ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT

FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 2020–2024 (USD BILLION)

FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024)

FIGURE 36 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 37 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024

FIGURE 38 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS)

FIGURE 39 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE)

FIGURE 40 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 41 EV/EBITDA OF KEY VENDORS

FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS

FIGURE 43 GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS

FIGURE 44 NOVO NORDISK A/S: COMPANY SNAPSHOT

FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT

FIGURE 46 SANOFI: COMPANY SNAPSHOT

FIGURE 47 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT

FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY

SNAPSHOT**FIGURE 49 INNOVENT: COMPANY SNAPSHOT****FIGURE 50 ZEALAND PHARMA: COMPANY SNAPSHOT****FIGURE 51 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT****FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT****FIGURE 53 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT****FIGURE 54 BIOCON: COMPANY SNAPSHOT****FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT****FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT**

I would like to order

Product name: GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033

Product link: <https://marketpublishers.com/r/GD274EBBE68FEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD274EBBE68FEN.html>